Drugs / BI 1701963
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04973163 | Sep 2021 → Nov 2026 expected | — | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04975256 | Jul 2021 → Nov 2022 | cancer of unknown primary site, lung cancer, malignant colon neoplasm, metastatic malignant neoplasm | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04835714 | Apr 2021 → Jan 2022 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT04627142 | Nov 2020 → Jan 2022 | colorectal cancer | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT04185883 | Dec 2019 → Dec 2026 expected | cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04111458 | Nov 2019 → Dec 2027 expected | — | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1701963 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04627142 ↗ |
| Action | Inhibit | “BI 1701963 is a small-molecule son of sevenless 1 (SOS1) inhibitor” PMID 42048384 ↗ Aug 2026 |
| Modality | Small molecule | “BI 1701963 is a small-molecule” PMID 42048384 ↗ Aug 2026 |
| Route | Oral | “During this time, they get tablets of BI 1701963 and trametinib once daily.” NCT04111458 ↗ |
| Target | SOS1 | “selectively binds to SOS1” PMID 42048384 ↗ Aug 2026 |